Trevena has been granted a patent for compounds and pharmaceutical compositions that modulate the activity of the S1P1 receptor. The patent claim includes a specific compound formula. GlobalData’s report on Trevena gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Trevena, Telomerase reverse transcriptase screening was a key innovation area identified from patents. Trevena's grant share as of February 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11912693B2) discloses a compound with a specific chemical formula that has potential applications in treating neuropathy, chemotherapy-induced neuropathic pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and pain associated with diabetic neuropathy. The patent claims cover the compound itself, pharmaceutical compositions containing the compound or its pharmaceutically acceptable salt, and methods for ameliorating these conditions by administering the compound or its salt to subjects in need.
Furthermore, the patent also includes claims related to a specific pharmaceutical composition comprising a compound with a defined formula, which can be used for ameliorating chemotherapy-induced neuropathic pain. The methods outlined in the patent involve administering the compound or its salt to individuals suffering from chemotherapy-induced neuropathic pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, or associated pain. These claims highlight the potential therapeutic benefits of the compound and its pharmaceutical compositions in addressing a range of neuropathic conditions, offering new possibilities for treatment and management in this medical domain.
To know more about GlobalData’s detailed insights on Trevena, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
